Literature DB >> 15382772

Chronic respiratory failure after lung resection: the role of pulmonary rehabilitation.

Bartolome R Celli1.   

Abstract

Pulmonary rehabilitation gradually has become the gold standard treatment for patients with severe lung disease, especially COPD. By definition, rehabilitation services are provided to patients with symptoms, most of whom have moderate-to-advanced lung disease. Because new therapeutic strategies, such as lung volume-reduction surgery and lung transplantation, require well-conditioned patients, pulmonary rehabilitation is becoming a crucial component of the overall treating strategy of many patients who heretofore were deemed untreatable. The positive results in several randomized trials have documented the effectiveness of pulmonary rehabilitation. Currently, pulmonary rehabilitation should be made available to all patients with symptomatic respiratory disease and be an integral part of any program considering high-risk surgery.

Entities:  

Mesh:

Year:  2004        PMID: 15382772     DOI: 10.1016/S1547-4127(04)00017-9

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  3 in total

1.  The effect of meeting physical activity guidelines for cancer survivors on quality of life following radical prostatectomy for prostate cancer.

Authors:  Daniel Santa Mina; Crissa L Guglietti; Shabbir M H Alibhai; Andrew G Matthew; Robin Kalnin; Nora Ahmad; Uri Lindner; John Trachtenberg
Journal:  J Cancer Surviv       Date:  2013-12-07       Impact factor: 4.442

2.  Which chronic obstructive pulmonary disease patients will be likely to attend consistently a pulmonary rehabilitation program?

Authors:  Salwa E Hassanein; Georgia L Narsavage; Sherrie Dixon Williams; Mary K Anthony; Lisaann S Gittner
Journal:  Perm J       Date:  2007

Review 3.  Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation.

Authors:  Simon Tiberi; Marcela Muñoz Torrico; Ananna Rahman; Maria Krutikov; Dina Visca; Denise Rossato Silva; Heinke Kunst; Giovanni Battista Migliori
Journal:  J Bras Pneumol       Date:  2019-04-25       Impact factor: 2.624

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.